John W. Creecy

VuCOMP, Inc. designs and develops computer aided detection systems for mammography. It offers M-Vu system, a medical device that screens mammogram images for abnormalities such as masses, architectural distortions, and calcifications. The company was founded by James Pike in 2001 and is headquartered in Plano, TX.

Apollo Endosurgery, Inc. provides medical devices for treatment of obesity. It offers OverStitch, an endoscopic suturing system that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope; and LAP-BAND, an adjustable gastric banding system for weight loss goals. The company was founded by Sergey Kantsevoy, Anthony Kalloo, Robert Hawes, Christopher J. Gostout and Dennis L. McWilliams in 2006 and is headquartered in Austin, TX.

BiOptix Diagnostics, Inc. develops biosensor for detection of bacteria and viruses. Its product 404pi offers scientists that require label-free, real-time detection of bio-molecular interactions an extremely high sensitivity, low noise instrument. The company was founded by Misha Plam, Slava Petropavlovskikh and Oyvind Nilsen in 2003 and is headquartered in Boulder, CO.

BiO2 Medical, Inc. engages in the design, development, and manufacturing of clinical products. The company was founded by Luis F. Angel, Christopher E. Banas, and Paul Castella in December 2006 and is headquartered in Golden, CO.

miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX.

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA.

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.